Voyager taps new business chief amid 'significant interest' from partners; Oncopeptides faces another CEO, CFO reset
Beth Shafer was taught to leave a place better than she found it. As Voyager Therapeutics’ new chief business officer, that’s exactly what she intends to do.
Voyager announced Monday that it tapped the Takeda veteran for its C-suite. Shafer will lead the business strategy as the company says its AAV capsid platform and neurology programs “continue to attract significant interest from third parties.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.